AccuStem Sciences, Inc. Announces Acquisition of Proprietary MSC Lung Cancer Screening Test
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 18 2025
0mins
Source: Newsfilter
AccuStem's Acquisition: AccuStem Sciences has acquired the license for the proprietary microRNA Signature Classifier (MSC) test, developed to enhance lung cancer screening accuracy, and plans to launch it in the US by 2026.
Benefits of MSC Test: The MSC test, when combined with low-dose computed tomography (LDCT), significantly improves diagnostic performance, reduces false positives, and aims to optimize patient management and healthcare costs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
